According to @StockMKTNewz, Novo Nordisk (NVO) shares moved lower this morning after the company announced failed results in an Alzheimer’s disease trial of semaglutide, as the study did not meet its main goal (source: @StockMKTNewz). CNBC reported the trials tested whether semaglutide—the active ingredient in Ozempic and Wegovy—could slow Alzheimer’s progression, and while Alzheimer’s-related biomarkers improved in two separate studies, the benefit did not translate into a delay in clinical progression, leading to a failed primary endpoint (source: CNBC). CNBC added that the biomarker improvements alone were insufficient to meet the key efficacy outcome of slowing disease progression, which is why the trial outcome is considered unsuccessful (source: CNBC). CNBC’s report did not reference any direct impact on cryptocurrency markets, indicating no explicit crypto linkage in this headline risk event (source: CNBC).